BioSpace News Archive

Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its CEO and co-founder, Emily M. Leproust, Ph.D., will receive the 2020 Rosalind Franklin Award for Leadership at the Biotechnology Innovation Organization (BIO) IMPACT conference.

Dr. Pardeep Nijhawan announces that his beneficial ownership of common shares in the capital of Edesa Biotech, Inc. has increased by more than 2% of the issued and outstanding Common Shares from the amount reported in the early warning report Dr. Nijhawan filed dated May 11, 2020.

The two companies bring together cloud-based mobile technologies to improve the identification, screening and matching of patients to precision-based clinical oncology trials

The Meningitis Research Foundation of Canada extends a warm welcome to its new senior medical advisor, Dr. Joanne Langley.

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.

The Foundation for the National Institutes of Health (FNIH) today bestowed its annual Trailblazer Prize for Clinician-Scientists to Michael Wilson , M.D., of the University of California San Francisco (UCSF). Dr. Wilson has received the Trailblazer Prize, along with a $10,000 honorarium, for pioneering a next-generat

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020 [18-September-2020] SEATTLE and VANCOUVER,

Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid ® , Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level. The products are being recalled because testing has found these lots to be sub potent. The product may have as low as 87% of the labeled amount

Coherus BioSciences, Inc., announced that effective September 17, 2020, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 118,000 shares of the common stock of the Company to six newly hired non-officer employees, with a per share exercise price of $19.07, the closing trading price on the grant date.

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline. “I am thrilled that Lori will be joining the Pipeline board as an indepe